Insider trade

CEO sold ~$2M of CORT shares in the open market

Traded May 1, 2026 · Filed May 6, 2026

Why it stands out

The boss of Corcept Therapeutics sold $2M of Corcept Therapeutics shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEOIndirect holding$1M+Pre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,003,860

Shares × reported transaction price

Timing vs results

1 day after results of Apr 30, 2026, 89 days before results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+9.4%	+1.2%	+8.3%
30 days	+39.3%	+0.5%	+38.7%
90 days	+110.5%	+5.1%	+105.4%

Past results only. Not a forecast.

Record ID: 0001193125-26-206540
Filed / recorded: May 6, 2026, 12:30 AM UTC
Added to OQRO: Oct 6, 2026, 7:14 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: CORCEPT THERAPEUTICS INC
Issuer CIK: 1088856
Ticker: CORT
Reporting person: Joseph K Belanoff
Relationship: Director, Officer
Officer title: Chief Executive Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: May 1, 2026
Transaction code: S
Shares / units: 40,000
Price per share: $50.10
Acquired / disposed: Disposed (D)
Shares owned after: 2,878,326
Ownership form: Indirect — Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02
Amendment: No

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.00 to $50.35 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

4mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance4mo ago

4mo ago

Derivative exercise or conversion — not an open-market buy.